Satralizumab BLA Accepted by FDA for Treatment of NMOSD

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

Source link

Related posts

Resident & Fellow Rounds


The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms


To Perceive Faces, Your Brain Relies on a Process Similar to Computer Face Recognition Systems


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World